Clarius Group LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 11.9% in the fourth quarter, ...
After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...
A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...
Sanofi India Ltd. key Products/Revenue Segments include Pharmaceutical Products, Sale of services, Other Operating Revenue, Export Incentives and Scrap for the year ending 31-Dec-2023.For the quarter ...